Regeneron to Report Q3 Earnings: What's in the Offing?

Biotech giant Regeneron Pharmaceuticals, Inc. (REGN) is slated to report third-quarter results on Oct. 31, 2024. The Zacks Consensus Estimate for revenues is pegged at $3.67 billion, while the same for earnings is pinned at $11.75 per share. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. REGN Faces Decline in Eylea Sales, Dupixent Fuels Growth Regeneron is currently facing challenges for its lead drug, Eylea, which is its primary growth engine. A significant chunk of Regeneron's rev ...